SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla receives Rs 424 cr demand notices from NPPA

05 Mar 2012 Evaluate

Cipla has received demand notices for Rs 424.64 crore from the National Pharmaceutical Pricing Authority (NPPA) towards interest for alleged drug overpricing. The firm that is currently fighting a case at the Supreme Court against the government, claimed the demand is not tenable and sustainable. The company has now received further demand notices from the government for Rs 424.64 crore towards interest up to January 2012. The interest is on the allegedly overcharged amounts in respect of the same drugs which are subject matter of litigation in the Honourable Supreme Court. The company had stated in an earlier filing that it had received demand notice of Rs 1,230 crore (inclusive of interest) from the government for the period July 1995 to April 2009.These demands are contrary to the orders of the Hon'ble Supreme Court of India and the company has received legal advice that entire amounts demanded by the government are not tenable and sustainable. Though the NPPA has been in litigation with Cipla over the issue, it has not been able to recover any amount from the Mumbai-based drugmaker. Under the Drugs Prices Control Order of 1995, NPPA is empowered to fix and regulate the prices of medicines kept under statutory price control. The organisation is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.

Cipla Share Price

1471.25 12.80 (0.88%)
06-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1913.05
Dr. Reddys Labs. 1368.75
Cipla 1471.25
Zydus Lifesciences 1148.05
Lupin 2492.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: